We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ferrex | LSE:FRX | London | Ordinary Share | GB00B649J414 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.45 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jan 2020 to Jan 2025
The U.S. Supreme Court on Monday refused to consider an appeal by Forest Laboratories Inc. (FRX) that sought to overturn a lower court ruling in favor of a generic drug maker that wants to market a generic version of Forest's depression drug Lexapro.
Without comment, the high court left in place an appeals court ruling that generic drug maker Caraco Pharmaceutical Laboratories Ltd. (CPD) could sue to challenge the validity of one of Forest's Lexapro patents.
Forest argued that Caraco could not bring a lawsuit because there was no legal controversy that would give the courts jurisdiction over the case. Forest said there was no legal dispute between the companies because it had agreed not to sue the generic drug maker for patent infringement.
Caraco's lawsuit now goes back to the lower courts for additional proceedings. The two companies are also engaged in another lawsuit involving a different Lexapro patent.
-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com
1 Year Ferrex Chart |
1 Month Ferrex Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
